A	O
screening	B:C0373483
assay	O
for	O
the	O
identification	O
of	O
host	O
cell	I:C1819995
requirements	O
and	O
antiviral	O
targets	I:C0003451
for	O
hepatitis	O
D	I:C0011226
virus	I:C0011226
infection	I:C0011226
.	O

A	O
screening	O
assay	B:C1510438
for	O
the	O
identification	O
of	O
host	O
cell	I:C1819995
requirements	O
and	O
antiviral	O
targets	I:C0003451
for	O
hepatitis	O
D	I:C0011226
virus	I:C0011226
infection	I:C0011226
.	O

A	O
screening	O
assay	O
for	O
the	O
identification	O
of	O
host	B:C1819995
cell	I:C1819995
requirements	O
and	O
antiviral	O
targets	I:C0003451
for	O
hepatitis	O
D	I:C0011226
virus	I:C0011226
infection	I:C0011226
.	O

A	O
screening	O
assay	O
for	O
the	O
identification	O
of	O
host	O
cell	I:C1819995
requirements	O
and	O
antiviral	B:C0003451
targets	I:C0003451
for	O
hepatitis	O
D	I:C0011226
virus	I:C0011226
infection	I:C0011226
.	O

A	O
screening	O
assay	O
for	O
the	O
identification	O
of	O
host	O
cell	I:C1819995
requirements	O
and	O
antiviral	O
targets	I:C0003451
for	O
hepatitis	B:C0011226
D	I:C0011226
virus	I:C0011226
infection	I:C0011226
.	O

Hepatitis	B:C0011220
delta	I:C0011220
virus	I:C0011220
(	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
)	O
is	O
a	O
minimalistic	O
satellite	I:C0036238
virus	I:C0036238
of	O
hepatitis	O
B	I:C0019169
virus	I:C0019169
(	O
hepatitis	O
B	I:C0019169
virus	I:C0019169
)	O
.	O

Hepatitis	O
delta	I:C0011220
virus	I:C0011220
(	O
Hepatitis	B:C0011220
delta	I:C0011220
virus	I:C0011220
)	O
is	O
a	O
minimalistic	O
satellite	I:C0036238
virus	I:C0036238
of	O
hepatitis	O
B	I:C0019169
virus	I:C0019169
(	O
hepatitis	O
B	I:C0019169
virus	I:C0019169
)	O
.	O

Hepatitis	O
delta	I:C0011220
virus	I:C0011220
(	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
)	O
is	O
a	O
minimalistic	B:C0036238
satellite	I:C0036238
virus	I:C0036238
of	O
hepatitis	O
B	I:C0019169
virus	I:C0019169
(	O
hepatitis	O
B	I:C0019169
virus	I:C0019169
)	O
.	O

Hepatitis	O
delta	I:C0011220
virus	I:C0011220
(	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
)	O
is	O
a	O
minimalistic	O
satellite	I:C0036238
virus	I:C0036238
of	O
hepatitis	B:C0019169
B	I:C0019169
virus	I:C0019169
(	O
hepatitis	O
B	I:C0019169
virus	I:C0019169
)	O
.	O

Hepatitis	O
delta	I:C0011220
virus	I:C0011220
(	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
)	O
is	O
a	O
minimalistic	O
satellite	I:C0036238
virus	I:C0036238
of	O
hepatitis	O
B	I:C0019169
virus	I:C0019169
(	O
hepatitis	B:C0019169
B	I:C0019169
virus	I:C0019169
)	O
.	O

HBV	O
/	O
Hepatitis	B:C0011220
delta	I:C0011220
virus	I:C0011220
co-infection	O
,	O
i.e.	O
"	O
hepatitis	O
D	I:C0011226
"	O
,	O
is	O
the	O
most	O
severe	O
form	O
of	O
viral	O
hepatitis	I:C0042721
.	O

HBV	O
/	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
co-infection	B:C0275524
,	O
i.e.	O
"	O
hepatitis	O
D	I:C0011226
"	O
,	O
is	O
the	O
most	O
severe	O
form	O
of	O
viral	O
hepatitis	I:C0042721
.	O

HBV	O
/	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
co-infection	O
,	O
i.e.	O
"	O
hepatitis	B:C0011226
D	I:C0011226
"	O
,	O
is	O
the	O
most	O
severe	O
form	O
of	O
viral	O
hepatitis	I:C0042721
.	O

HBV	O
/	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
co-infection	O
,	O
i.e.	O
"	O
hepatitis	O
D	I:C0011226
"	O
,	O
is	O
the	O
most	O
severe	O
form	O
of	O
viral	B:C0042721
hepatitis	I:C0042721
.	O

No	O
effective	O
therapy	B:C0087111
for	O
HDV	O
infection	I:C0011226
is	O
available	O
partly	O
due	O
to	O
the	O
fact	O
that	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
is	O
a	O
highly	O
host	O
-	O
dependent	O
virus	O
devoid	O
of	O
any	O
potentially	O
drugable	O
enzyme	I:C0014442
encoded	O
in	O
its	O
small	O
genome	O
.	O

No	O
effective	O
therapy	O
for	O
HDV	B:C0011226
infection	I:C0011226
is	O
available	O
partly	O
due	O
to	O
the	O
fact	O
that	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
is	O
a	O
highly	O
host	O
-	O
dependent	O
virus	O
devoid	O
of	O
any	O
potentially	O
drugable	O
enzyme	I:C0014442
encoded	O
in	O
its	O
small	O
genome	O
.	O

No	O
effective	O
therapy	O
for	O
HDV	O
infection	I:C0011226
is	O
available	O
partly	O
due	O
to	O
the	O
fact	O
that	O
Hepatitis	B:C0011220
delta	I:C0011220
virus	I:C0011220
is	O
a	O
highly	O
host	O
-	O
dependent	O
virus	O
devoid	O
of	O
any	O
potentially	O
drugable	O
enzyme	I:C0014442
encoded	O
in	O
its	O
small	O
genome	O
.	O

No	O
effective	O
therapy	O
for	O
HDV	O
infection	I:C0011226
is	O
available	O
partly	O
due	O
to	O
the	O
fact	O
that	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
is	O
a	O
highly	O
host	O
-	O
dependent	O
virus	B:C0042776
devoid	O
of	O
any	O
potentially	O
drugable	O
enzyme	I:C0014442
encoded	O
in	O
its	O
small	O
genome	O
.	O

No	O
effective	O
therapy	O
for	O
HDV	O
infection	I:C0011226
is	O
available	O
partly	O
due	O
to	O
the	O
fact	O
that	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
is	O
a	O
highly	O
host	O
-	O
dependent	O
virus	O
devoid	O
of	O
any	O
potentially	O
drugable	B:C0014442
enzyme	I:C0014442
encoded	O
in	O
its	O
small	O
genome	O
.	O

No	O
effective	O
therapy	O
for	O
HDV	O
infection	I:C0011226
is	O
available	O
partly	O
due	O
to	O
the	O
fact	O
that	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
is	O
a	O
highly	O
host	O
-	O
dependent	O
virus	O
devoid	O
of	O
any	O
potentially	O
drugable	O
enzyme	I:C0014442
encoded	O
in	O
its	O
small	O
genome	B:C0017428
.	O

In	O
this	O
study	B:C2603343
we	O
present	O
a	O
semi-automated	O
method	I:C0025663
to	O
evaluate	O
HDV	O
infection	I:C0011226
and	O
replication	O
under	O
the	O
influence	O
of	O
different	O
drugs	O
.	O

In	O
this	O
study	O
we	O
present	O
a	O
semi-automated	B:C0025663
method	I:C0025663
to	O
evaluate	O
HDV	O
infection	I:C0011226
and	O
replication	O
under	O
the	O
influence	O
of	O
different	O
drugs	O
.	O

In	O
this	O
study	O
we	O
present	O
a	O
semi-automated	O
method	I:C0025663
to	O
evaluate	B:C0220825
HDV	O
infection	I:C0011226
and	O
replication	O
under	O
the	O
influence	O
of	O
different	O
drugs	O
.	O

In	O
this	O
study	O
we	O
present	O
a	O
semi-automated	O
method	I:C0025663
to	O
evaluate	O
HDV	B:C0011226
infection	I:C0011226
and	O
replication	O
under	O
the	O
influence	O
of	O
different	O
drugs	O
.	O

In	O
this	O
study	O
we	O
present	O
a	O
semi-automated	O
method	I:C0025663
to	O
evaluate	O
HDV	O
infection	I:C0011226
and	O
replication	B:C0042774
under	O
the	O
influence	O
of	O
different	O
drugs	O
.	O

In	O
this	O
study	O
we	O
present	O
a	O
semi-automated	O
method	I:C0025663
to	O
evaluate	O
HDV	O
infection	I:C0011226
and	O
replication	O
under	O
the	O
influence	O
of	O
different	O
drugs	B:C1254351
.	O

We	O
utilized	O
a	O
Huh	B:C0007600
-	I:C0007600
7/	I:C0007600
hNTCP	I:C0007600
cell	I:C0007600
culture	I:C0007600
based	O
system	O
in	O
a	O
96	O
-	O
well	O
plate	I:C4283957
format	I:C4283957
,	O
an	O
automated	O
microscope	O
and	O
image	O
acquisition	O
as	O
well	O
as	O
analysis	O
with	O
the	O
CellProfiler	O
software	I:C0037589
to	O
quantify	O
the	O
impact	O
of	O
these	O
drugs	O
on	O
HDV	O
infection	I:C0011226
.	O

We	O
utilized	O
a	O
Huh	O
-	I:C0007600
7/	I:C0007600
hNTCP	I:C0007600
cell	I:C0007600
culture	I:C0007600
based	O
system	O
in	O
a	O
96	O
-	O
well	B:C4283957
plate	I:C4283957
format	I:C4283957
,	O
an	O
automated	O
microscope	O
and	O
image	O
acquisition	O
as	O
well	O
as	O
analysis	O
with	O
the	O
CellProfiler	O
software	I:C0037589
to	O
quantify	O
the	O
impact	O
of	O
these	O
drugs	O
on	O
HDV	O
infection	I:C0011226
.	O

We	O
utilized	O
a	O
Huh	O
-	I:C0007600
7/	I:C0007600
hNTCP	I:C0007600
cell	I:C0007600
culture	I:C0007600
based	O
system	O
in	O
a	O
96	O
-	O
well	O
plate	I:C4283957
format	I:C4283957
,	O
an	O
automated	O
microscope	B:C0181839
and	O
image	O
acquisition	O
as	O
well	O
as	O
analysis	O
with	O
the	O
CellProfiler	O
software	I:C0037589
to	O
quantify	O
the	O
impact	O
of	O
these	O
drugs	O
on	O
HDV	O
infection	I:C0011226
.	O

We	O
utilized	O
a	O
Huh	O
-	I:C0007600
7/	I:C0007600
hNTCP	I:C0007600
cell	I:C0007600
culture	I:C0007600
based	O
system	O
in	O
a	O
96	O
-	O
well	O
plate	I:C4283957
format	I:C4283957
,	O
an	O
automated	O
microscope	O
and	O
image	O
acquisition	O
as	O
well	O
as	O
analysis	B:C0936012
with	O
the	O
CellProfiler	O
software	I:C0037589
to	O
quantify	O
the	O
impact	O
of	O
these	O
drugs	O
on	O
HDV	O
infection	I:C0011226
.	O

We	O
utilized	O
a	O
Huh	O
-	I:C0007600
7/	I:C0007600
hNTCP	I:C0007600
cell	I:C0007600
culture	I:C0007600
based	O
system	O
in	O
a	O
96	O
-	O
well	O
plate	I:C4283957
format	I:C4283957
,	O
an	O
automated	O
microscope	O
and	O
image	O
acquisition	O
as	O
well	O
as	O
analysis	O
with	O
the	O
CellProfiler	B:C0037589
software	I:C0037589
to	O
quantify	O
the	O
impact	O
of	O
these	O
drugs	O
on	O
HDV	O
infection	I:C0011226
.	O

We	O
utilized	O
a	O
Huh	O
-	I:C0007600
7/	I:C0007600
hNTCP	I:C0007600
cell	I:C0007600
culture	I:C0007600
based	O
system	O
in	O
a	O
96	O
-	O
well	O
plate	I:C4283957
format	I:C4283957
,	O
an	O
automated	O
microscope	O
and	O
image	O
acquisition	O
as	O
well	O
as	O
analysis	O
with	O
the	O
CellProfiler	O
software	I:C0037589
to	O
quantify	O
the	O
impact	O
of	O
these	O
drugs	B:C1254351
on	O
HDV	O
infection	I:C0011226
.	O

We	O
utilized	O
a	O
Huh	O
-	I:C0007600
7/	I:C0007600
hNTCP	I:C0007600
cell	I:C0007600
culture	I:C0007600
based	O
system	O
in	O
a	O
96	O
-	O
well	O
plate	I:C4283957
format	I:C4283957
,	O
an	O
automated	O
microscope	O
and	O
image	O
acquisition	O
as	O
well	O
as	O
analysis	O
with	O
the	O
CellProfiler	O
software	I:C0037589
to	O
quantify	O
the	O
impact	O
of	O
these	O
drugs	O
on	O
HDV	B:C0011226
infection	I:C0011226
.	O

For	O
validation	B:C1519941
,	O
three	O
groups	O
of	O
potential	O
anti-HDV	O
agents	I:C0003451
were	O
evaluated	O
:	O

For	O
validation	O
,	O
three	O
groups	O
of	O
potential	O
anti-HDV	B:C0003451
agents	I:C0003451
were	O
evaluated	O
:	O

For	O
validation	O
,	O
three	O
groups	O
of	O
potential	O
anti-HDV	O
agents	I:C0003451
were	O
evaluated	B:C0220825
:	O

To	O
target	O
ribozyme	B:C0080125
activity	O
of	O
HDV	O
RNA	I:C0486926
,	O
we	O
screened	O
ribozyme	O
inhibitors	O
but	O
only	O
observed	O
marked	O
toxicity	O
.	O

To	O
target	O
ribozyme	O
activity	B:C0243102
of	O
HDV	O
RNA	I:C0486926
,	O
we	O
screened	O
ribozyme	O
inhibitors	O
but	O
only	O
observed	O
marked	O
toxicity	O
.	O

To	O
target	O
ribozyme	O
activity	O
of	O
HDV	B:C0486926
RNA	I:C0486926
,	O
we	O
screened	O
ribozyme	O
inhibitors	O
but	O
only	O
observed	O
marked	O
toxicity	O
.	O

To	O
target	O
ribozyme	O
activity	O
of	O
HDV	O
RNA	I:C0486926
,	O
we	O
screened	B:C0373483
ribozyme	O
inhibitors	O
but	O
only	O
observed	O
marked	O
toxicity	O
.	O

To	O
target	O
ribozyme	O
activity	O
of	O
HDV	O
RNA	I:C0486926
,	O
we	O
screened	O
ribozyme	B:C0080125
inhibitors	O
but	O
only	O
observed	O
marked	O
toxicity	O
.	O

To	O
target	O
ribozyme	O
activity	O
of	O
HDV	O
RNA	I:C0486926
,	O
we	O
screened	O
ribozyme	O
inhibitors	B:C0014432
but	O
only	O
observed	O
marked	O
toxicity	O
.	O

Testing	O
innate	O
antiviral	B:C1155328
mediators	O
showed	O
that	O
interferons	O
alpha	I:C0021734
-	I:C0021734
2a	I:C0021734
and	O
beta	O
-	I:C0254119
1a	I:C0254119
had	O
a	O
specific	O
inhibitory	O
effect	O
on	O
HDV	O
infection	I:C0011226
.	O

Testing	O
innate	O
antiviral	O
mediators	B:C0301974
showed	O
that	O
interferons	O
alpha	I:C0021734
-	I:C0021734
2a	I:C0021734
and	O
beta	O
-	I:C0254119
1a	I:C0254119
had	O
a	O
specific	O
inhibitory	O
effect	O
on	O
HDV	O
infection	I:C0011226
.	O

Testing	O
innate	O
antiviral	O
mediators	O
showed	O
that	O
interferons	B:C0021734
alpha	I:C0021734
-	I:C0021734
2a	I:C0021734
and	O
beta	O
-	I:C0254119
1a	I:C0254119
had	O
a	O
specific	O
inhibitory	O
effect	O
on	O
HDV	O
infection	I:C0011226
.	O

Testing	O
innate	O
antiviral	O
mediators	O
showed	O
that	O
interferons	O
alpha	I:C0021734
-	I:C0021734
2a	I:C0021734
and	O
beta	B:C0254119
-	I:C0254119
1a	I:C0254119
had	O
a	O
specific	O
inhibitory	O
effect	O
on	O
HDV	O
infection	I:C0011226
.	O

Testing	O
innate	O
antiviral	O
mediators	O
showed	O
that	O
interferons	O
alpha	I:C0021734
-	I:C0021734
2a	I:C0021734
and	O
beta	O
-	I:C0254119
1a	I:C0254119
had	O
a	O
specific	O
inhibitory	O
effect	O
on	O
HDV	B:C0011226
infection	I:C0011226
.	O

Finally	O
,	O
we	O
screened	B:C0373483
a	O
library	O
of	O
160	O
human	O
kinase	O
inhibitors	I:C3537035
covering	O
all	O
parts	O
of	O
the	O
human	O
kinome	O
.	O

Finally	O
,	O
we	O
screened	O
a	O
library	B:C0023621
of	O
160	O
human	O
kinase	O
inhibitors	I:C3537035
covering	O
all	O
parts	O
of	O
the	O
human	O
kinome	O
.	O

Finally	O
,	O
we	O
screened	O
a	O
library	O
of	O
160	O
human	B:C0086418
kinase	O
inhibitors	I:C3537035
covering	O
all	O
parts	O
of	O
the	O
human	O
kinome	O
.	O

Finally	O
,	O
we	O
screened	O
a	O
library	O
of	O
160	O
human	O
kinase	B:C3537035
inhibitors	I:C3537035
covering	O
all	O
parts	O
of	O
the	O
human	O
kinome	O
.	O

Finally	O
,	O
we	O
screened	O
a	O
library	O
of	O
160	O
human	O
kinase	O
inhibitors	I:C3537035
covering	O
all	O
parts	O
of	O
the	O
human	B:C0086418
kinome	O
.	O

Finally	O
,	O
we	O
screened	O
a	O
library	O
of	O
160	O
human	O
kinase	O
inhibitors	I:C3537035
covering	O
all	O
parts	O
of	O
the	O
human	O
kinome	B:C3829378
.	O

Overall	O
,	O
only	O
inhibitors	B:C0014432
targeting	O
the	O
tyrosine	O
kinase	I:C0033640
-	I:C0033640
like	I:C0033640
group	I:C0033640
had	O
significant	O
average	O
anti-HDV	O
activity	I:C1155328
.	O

Overall	O
,	O
only	O
inhibitors	O
targeting	O
the	O
tyrosine	B:C0033640
kinase	I:C0033640
-	I:C0033640
like	I:C0033640
group	I:C0033640
had	O
significant	O
average	O
anti-HDV	O
activity	I:C1155328
.	O

Overall	O
,	O
only	O
inhibitors	O
targeting	O
the	O
tyrosine	O
kinase	I:C0033640
-	I:C0033640
like	I:C0033640
group	I:C0033640
had	O
significant	O
average	O
anti-HDV	B:C1155328
activity	I:C1155328
.	O

Looking	O
at	O
individual	O
substances	B:C1254351
,	O
kenpaullone	O
,	O
a	O
GSK	O
-	I:C0244988
3	I:C0244988
β	I:C0244988
and	O
Cdk	O
inhibitor	I:C1511576
,	O
had	O
the	O
highest	O
selective	O
index	I:C0918012
of	O
3.44	O
.	O

Looking	O
at	O
individual	O
substances	O
,	O
kenpaullone	B:C0768461
,	O
a	O
GSK	O
-	I:C0244988
3	I:C0244988
β	I:C0244988
and	O
Cdk	O
inhibitor	I:C1511576
,	O
had	O
the	O
highest	O
selective	O
index	I:C0918012
of	O
3.44	O
.	O

Looking	O
at	O
individual	O
substances	O
,	O
kenpaullone	O
,	O
a	O
GSK	B:C0244988
-	I:C0244988
3	I:C0244988
β	I:C0244988
and	O
Cdk	O
inhibitor	I:C1511576
,	O
had	O
the	O
highest	O
selective	O
index	I:C0918012
of	O
3.44	O
.	O

Looking	O
at	O
individual	O
substances	O
,	O
kenpaullone	O
,	O
a	O
GSK	O
-	I:C0244988
3	I:C0244988
β	I:C0244988
and	O
Cdk	B:C1511576
inhibitor	I:C1511576
,	O
had	O
the	O
highest	O
selective	O
index	I:C0918012
of	O
3.44	O
.	O

Looking	O
at	O
individual	O
substances	O
,	O
kenpaullone	O
,	O
a	O
GSK	O
-	I:C0244988
3	I:C0244988
β	I:C0244988
and	O
Cdk	O
inhibitor	I:C1511576
,	O
had	O
the	O
highest	O
selective	B:C0918012
index	I:C0918012
of	O
3.44	O
.	O

Thus	O
,	O
we	O
provide	O
a	O
potentially	O
useful	O
tool	B:C0025663
to	O
screen	O
for	O
substances	O
with	O
anti-HDV	O
activity	I:C1155328
and	O
novel	O
insights	O
into	O
interactions	O
between	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
replication	O
and	O
the	O
human	O
kinome	O
.	O

Thus	O
,	O
we	O
provide	O
a	O
potentially	O
useful	O
tool	O
to	O
screen	B:C0220908
for	O
substances	O
with	O
anti-HDV	O
activity	I:C1155328
and	O
novel	O
insights	O
into	O
interactions	O
between	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
replication	O
and	O
the	O
human	O
kinome	O
.	O

Thus	O
,	O
we	O
provide	O
a	O
potentially	O
useful	O
tool	O
to	O
screen	O
for	O
substances	B:C1254351
with	O
anti-HDV	O
activity	I:C1155328
and	O
novel	O
insights	O
into	O
interactions	O
between	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
replication	O
and	O
the	O
human	O
kinome	O
.	O

Thus	O
,	O
we	O
provide	O
a	O
potentially	O
useful	O
tool	O
to	O
screen	O
for	O
substances	O
with	O
anti-HDV	B:C1155328
activity	I:C1155328
and	O
novel	O
insights	O
into	O
interactions	O
between	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
replication	O
and	O
the	O
human	O
kinome	O
.	O

Thus	O
,	O
we	O
provide	O
a	O
potentially	O
useful	O
tool	O
to	O
screen	O
for	O
substances	O
with	O
anti-HDV	O
activity	I:C1155328
and	O
novel	O
insights	B:C0233820
into	O
interactions	O
between	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
replication	O
and	O
the	O
human	O
kinome	O
.	O

Thus	O
,	O
we	O
provide	O
a	O
potentially	O
useful	O
tool	O
to	O
screen	O
for	O
substances	O
with	O
anti-HDV	O
activity	I:C1155328
and	O
novel	O
insights	O
into	O
interactions	O
between	O
Hepatitis	B:C0011220
delta	I:C0011220
virus	I:C0011220
replication	O
and	O
the	O
human	O
kinome	O
.	O

Thus	O
,	O
we	O
provide	O
a	O
potentially	O
useful	O
tool	O
to	O
screen	O
for	O
substances	O
with	O
anti-HDV	O
activity	I:C1155328
and	O
novel	O
insights	O
into	O
interactions	O
between	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
replication	B:C0042774
and	O
the	O
human	O
kinome	O
.	O

Thus	O
,	O
we	O
provide	O
a	O
potentially	O
useful	O
tool	O
to	O
screen	O
for	O
substances	O
with	O
anti-HDV	O
activity	I:C1155328
and	O
novel	O
insights	O
into	O
interactions	O
between	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
replication	O
and	O
the	O
human	B:C0086418
kinome	O
.	O

Thus	O
,	O
we	O
provide	O
a	O
potentially	O
useful	O
tool	O
to	O
screen	O
for	O
substances	O
with	O
anti-HDV	O
activity	I:C1155328
and	O
novel	O
insights	O
into	O
interactions	O
between	O
Hepatitis	O
delta	I:C0011220
virus	I:C0011220
replication	O
and	O
the	O
human	O
kinome	B:C3829378
.	O

